ZBH: Annual Thesis 2025–2026
FY25 revenue $8.23B (+7%); Op income $1.36B (+6%); Net income $705M (-22%); EPS $3.55. Organic CC growth +5.4% Q4 (5th consecutive year mid-single digit+). Robotics + Persona OsteoTide + Z1 stem driving share gains. FY26 guide: organic CC +1-3%, adj EPS $8.30-$8.45, FCF growth +8-10%.
Key takeaways
- Five-year mid-single-digit organic streak intact. Q4 organic constant currency +5.4% (US +5.7%, International +5%). FY25 marks the fifth consecutive year of MSD+ organic growth — sustained execution against a category that historically grew low-single-digit.
- Knee + Hip + Robotics carrying the bag. US Knee +6% in Q4 driven by Persona OsteoTide ortho knee (35% penetration by year-end). US Hip +8% on Z1 triple-taper stem penetration. Robotics & Navigation +10%+ on capital sales — a leading indicator for procedure mix.
- GAAP NI down 22% is misleading. $705M net income (vs $904M FY24) reflects M&A-related charges (likely Paragon 28 acquisition + integration costs). Operating income +6% YoY — operationally fine. EPS guide for FY26 is $8.30-$8.45, well above the $3.55 GAAP this year.
- FY26 guide is a "muscle memory" year. Organic CC +1-3% (lower than five-year run-rate, conservative), adj EPS $8.30-$8.45, FCF +8-10%. FX +50bp tailwind to revenue. Paragon 28 contributes ~100bp to reported sales growth.
- Cash machine remains underrated. FCF $1.47B FY25 (vs $1.14B FY24, +29%). Buyback $-487M down from $-868M FY24 (deal-related conservatism). Dividend $-190M held.
Business
Zimmer Biomet is the #1 or #2 global orthopedic medical device player by category, with five product franchises:
- Knees (~30% of revenue). Persona, NexGen, Vanguard. Persona OsteoTide is the FY25 share-driver — lower-cost, faster-loading variant taking real-world penetration to ~35% in the US by year-end.
- Hips (~22%). Z1 (triple-taper stem) the lead launch driving US +8% Q4. Avenir, Taperloc, Continuum acetabular.
- Sports Medicine, Extremities, Trauma (S.E.T.) (~22%). Subax (shoulder), DigiMatch (small bones), Trabecular Metal trauma. Acquired Embody and Paragon 28 (foot & ankle) for tuck-in growth.
- Spine + Cranio Maxillofacial Thoracic (S/CMFT) (~12%). EMPOWR spine + ZB CMFT. Mid-teens growth in Q4 — outperforming category.
- Dental + Other (~14%). Implants, biologics, robotics capital, navigation, and software.
Robotics franchise (ROSA Knee + Hip + Recon) bundled into Knees + Hips revenue but tracked separately; capital placements are a key forward indicator for procedure share.
Paragon 28 acquisition (foot & ankle specialist, closed in 2025) adds ~100bp to FY26 reported revenue; integrating into S.E.T. franchise.
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 6.94 | 7.39 | 7.68 | 8.23 |
| Gross profit ($B) | 4.92 | 5.31 | 5.49 | 5.07 |
| Gross margin | 70.9% | 71.8% | 71.5% | 61.6% |
| Op income ($B) | 0.70 | 1.28 | 1.29 | 1.36 |
| Op margin | 10.0% | 17.3% | 16.7% | 16.5% |
| EBITDA ($B) | 1.49 | 2.22 | 2.25 | 2.22 |
| Net income ($M) | 231 | 1,024 | 904 | 705 |
| Diluted EPS ($) | 1.10 | 4.88 | 4.43 | 3.55 |
| FCF ($B) | 1.07 | 1.19 | 1.14 | 1.47 |
| Capex ($M) | -218 | -394 | -357 | -224 |
| Dividends ($M) | -201 | -201 | -196 | -190 |
| Buyback ($M) | -126 | -692 | -868 | -487 |
Two anomalies to flag:
- Gross margin step-down to 61.6% from 71.5% FY24 looks alarming, but reflects revised classification — likely restatement of cost of goods to include certain royalty / amortization items previously below the GP line. Operating margin held at 16.5% which is the cleaner profitability signal.
- Capex moderated to $-224M (from $-357M FY24), funding came down as PPE refresh stage completed.
The five-year organic CC growth streak remains the cleanest single line on the underlying business quality.
Capital allocation
- Capex: $-224M FY25, ~2.7% of revenue. Down from $-357M as PPE program normalized.
- Dividends: $-190M FY25, held flat at $0.96/share annual. Well-covered by FCF.
- Buybacks: $-487M FY25 (vs $-868M FY24). Reduced pace likely funds Paragon 28 acquisition + integration. Still meaningful at ~3% of market cap.
- M&A: Paragon 28 closed in 2025 (~100bp FY26 reported revenue contribution). Embody also acquired earlier. Tuck-in cadence of ~1-2 deals/year.
- FCF: $1.47B FY25 (+29% YoY) — the strongest absolute number in the four-year window. Mgmt guides FCF growth +8-10% in FY26.
FY26 outlook (per Q4 2025 management call, 2026-02-10)
| FY26 guide | Range |
|---|---|
| Organic constant-currency revenue | +1% to +3% |
| Adjusted EPS | $8.30 to $8.45 |
| Free cash flow growth | +8% to +10% |
| FX impact on revenue | +50bp tailwind |
| Paragon 28 contribution to reported | ~100bp |
The +1-3% organic CC guide is the lowest in five years — explicitly conservative. Management has a track record of meeting or beating this kind of guide. The walk: FX +50bp + Paragon 28 +100bp = +150-250bp inorganic + organic +1-3% → reported FY26 +2.5-5.5%.
Adj EPS guide $8.30-$8.45 vs FY25 reported (likely adj basis ~$8.00) implies +4-5% earnings growth — slightly above revenue growth, suggesting mild operating leverage + buyback contribution.
Key risks
- Persona OsteoTide / Z1 saturation: Two new lead products driving US share. If penetration plateaus before reaching modeled levels, the organic CC growth rate normalizes lower.
- Procedure volumes: Knee + hip procedures are correlated to elective surgery throughput. Hospital staffing or insurance reauthorization tightening would compress volume.
- Robotics ROI: ROSA capital placements are heavy upfront cost for hospital systems; if hospital capital budgets compress, the procedure-mix lever weakens.
- Paragon 28 integration: Foot & ankle is a different sales motion from large joints; integration challenges could pressure the +100bp FY26 contribution math.
- GLP-1 demand impact: Long-term theme: weight loss drugs reducing obesity-driven joint replacement volume. Currently mgmt frames as net positive (more healthier patients eligible) but this is debated.
- FX volatility: 50bp guide tailwind assumes current rates; ZBH has ~40% international exposure.
Bottom line
ZBH FY25 is a clean execution year masked by GAAP-NI decline. Five years of mid-single-digit organic CC growth + strong FCF + disciplined capital return + tuck-in M&A + new product cycle (OsteoTide, Z1, ROSA) makes this one of the cleaner med-device compounders. FY26 guide is intentionally conservative; the question is whether ZBH continues to beat the +1-3% organic floor. If yes, FY26 prints adj EPS in $8.40-$8.60 range. The structural risk is GLP-1 demand impact on long-term joint replacement TAM, which is a 5-10 year question rather than FY26 issue.
Citations
- Zimmer Biomet Holdings FY25 Form 10-K (filed February 2026, SEC EDGAR).
- Zimmer Biomet Q4 2025 earnings call, 2026-02-10 — segment organic CC detail, FY26 guide ($8.30-$8.45 adj EPS, +1-3% organic, +8-10% FCF growth), Paragon 28 contribution.
- Persona OsteoTide and Z1 stem product launch disclosures (Q1–Q3 FY25 earnings calls).
- Internal financial_statements view (consolidated annual + cash flow + capital return).